pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›ZEPBOUND
drug · protein
save

ZEPBOUND

Marketedupdated 6mo ago
/ tur-ZEP-ə-tyde /
by $LLY ELI LILLY & Co🔗 ChEMBL
Approved
annual revenue · 2024–2024peak $4.9B
2024: $4.9B2024$4.9B
community read0 votes

🐶 often sniffed alongside

top 6
  • drugMOUNJARO112 co-mentions · 40 sources
  • drugtirzepatide112 co-mentions · 40 sources
  • tagApproval96 co-mentions · 24 sources
  • companyEli Lilly and Co48 co-mentions · 24 sources
  • tagRecall16 co-mentions · 16 sources
  • drugcyanocobalamin2 co-mentions · 2 sources

Protein drug with a maximum clinical stage of Approval (across all indications), with 6 approved and 8 investigational indications.

indications

investigational
Obesity

targets

Glucagon-like peptide 1 receptorGastric inhibitory polypeptide receptor

all catalysts(24)

approval · 24
May 13, 2022
approval
$LLY1382.75-2.32%
5y ago
MOUNJARO (TIRZEPATIDE) — FDA approval
ZEPBOUND
→
Jul 28, 2023
approval
$LLY1382.75-2.32%
3y ago
MOUNJARO (TIRZEPATIDE) — FDA approval
ZEPBOUND
→
Jul 28, 2023
approval
$LLY1382.75-2.32%
3y ago
MOUNJARO (TIRZEPATIDE) — FDA approval
ZEPBOUND
→
Nov 8, 2023
approval
$LLY1382.75-2.32%
3y ago
ZEPBOUND (TIRZEPATIDE) — FDA approval
ZEPBOUND
→
Mar 28, 2024
approval
$LLY1382.75-2.32%
3y ago
ZEPBOUND (TIRZEPATIDE) — FDA approval
ZEPBOUND
→
Oct 18, 2024
approval
$LLY1382.75-2.32%
2y ago
ZEPBOUND (TIRZEPATIDE) — FDA approval
ZEPBOUND
→
Oct 18, 2024
approval
$LLY1382.75-2.32%
2y ago
ZEPBOUND (TIRZEPATIDE) — FDA approval
ZEPBOUND
→
Oct 18, 2024
approval
$LLY1382.75-2.32%
2y ago
ZEPBOUND (TIRZEPATIDE) — FDA approval
ZEPBOUND
→
Oct 18, 2024
approval
$LLY1382.75-2.32%
2y ago
ZEPBOUND (TIRZEPATIDE) — FDA approval
ZEPBOUND
→
Oct 18, 2024
approval
$LLY1382.75-2.32%
2y ago
ZEPBOUND (TIRZEPATIDE) — FDA approval
ZEPBOUND
→
Nov 1, 2024
approval
$LLY1382.75-2.32%
2y ago
MOUNJARO (TIRZEPATIDE) — FDA approval
ZEPBOUND
→
Nov 1, 2024
approval
$LLY1382.75-2.32%
2y ago
MOUNJARO (TIRZEPATIDE) — FDA approval
ZEPBOUND
→
Nov 1, 2024
approval
$LLY1382.75-2.32%
2y ago
MOUNJARO (TIRZEPATIDE) — FDA approval
ZEPBOUND
→
Dec 20, 2024
approval
$LLY1382.75-2.32%
2y ago
ZEPBOUND (TIRZEPATIDE) — FDA approval
ZEPBOUND
→
Feb 7, 2025
approval
$LLY1382.75-2.32%
2y ago
ZEPBOUND (TIRZEPATIDE) — FDA approval
ZEPBOUND
→
May 28, 2025
approval
$LLY1382.75-2.32%
1y ago
MOUNJARO (TIRZEPATIDE) — FDA approval
ZEPBOUND
→
Sep 25, 2025
approval
$LLY1382.75-2.32%
1y ago
ZEPBOUND (TIRZEPATIDE) — FDA approval
ZEPBOUND
→
Sep 25, 2025
approval
$LLY1382.75-2.32%
1y ago
MOUNJARO (TIRZEPATIDE) — FDA approval
ZEPBOUND
→
Dec 19, 2025
approval
$LLY1382.75-2.32%
11mo ago
MOUNJARO (TIRZEPATIDE) — FDA approval
ZEPBOUND
→
Jan 7, 2026
approval
$LLY1382.75-2.32%
11mo ago
MOUNJARO (TIRZEPATIDE) — FDA approval
ZEPBOUND
→
Jan 7, 2026
approval
$LLY1382.75-2.32%
11mo ago
ZEPBOUND (TIRZEPATIDE) — FDA approval
ZEPBOUND
→
Jan 20, 2026
approval
$LLY1382.75-2.32%
10mo ago
MOUNJARO (TIRZEPATIDE) — FDA approval
ZEPBOUND
→
Jan 20, 2026
approval
$LLY1382.75-2.32%
10mo ago
ZEPBOUND (TIRZEPATIDE) — FDA approval
ZEPBOUND
→
Feb 25, 2026
approval
$LLY1382.75-2.32%
9mo ago
ZEPBOUND (TIRZEPATIDE) — FDA approval
ZEPBOUND
→
view all 24 catalysts →

Trials studying ZEPBOUND

  • phase2A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweightcompletedn=252
  • phase4A Study of Tirzepatide Compared With Intensified Conventional Care in Adult Participants With Type 2 Diabetesactive not recruitingn=794
  • phase1Impact of Using a GLP1 on Treatment Related Side Effects of Lung Cancer Patients Receiving Lorlatinibrecruitingn=30
  • phase3A Study of EloraTZP in Adult Participants With Obesity or Overweight and Type 2 Diabetesnot yet recruitingn=1,000
  • phase1A Research Study Investigating How Adults With Overweight or Obesity, With or Without Type 2 Diabetes, Tolerate Switching to a New Treatment (Zenagamtide) From Their Current Tirzepatide Medicationrecruitingn=60
  • phase3Efficacy, Safety, and Pharmacokinetics of Tirzepatide (LY3298176) Once Weekly Versus Placebo in Pediatric Participants 6 to Less Than 12 Years of Age Who Have Obesity (ADVANCE-SURMOUNT-KIDS)not yet recruitingn=150
  • phase2Efficacy and Safety of Tirzepatide Versus Placebo or Lisdexamfetamine Dimesylate for Binge-Eating Disorderrecruitingn=105
  • phase3A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)recruitingn=300

Patent cliff

source: FDA Orange Book
first barrier falls
May 13, 2027
174 days

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (216)

  • Dec 30, 2041method-of-use (U-4193)US 12295987
  • Dec 30, 2041method-of-use (U-4192)US 12295987
  • Dec 30, 2041method-of-use (U-4192)US 12295987
  • Dec 30, 2041method-of-use (U-4193)US 12295987
  • Dec 30, 2041method-of-use (U-4192)US 12295987
  • Dec 30, 2041method-of-use (U-4192)US 12295987
  • Dec 30, 2041method-of-use (U-4192)US 12295987
  • Dec 30, 2041method-of-use (U-4192)US 12295987
  • Dec 30, 2041method-of-use (U-4192)US 12295987
  • Dec 30, 2041method-of-use (U-4192)US 12295987
  • Dec 30, 2041method-of-use (U-4192)US 12295987
  • Dec 30, 2041method-of-use (U-4192)US 12295987
  • Dec 30, 2041method-of-use (U-4192)US 12295987
  • Dec 30, 2041method-of-use (U-4192)US 12295987
  • Dec 30, 2041method-of-use (U-4193)US 12295987
  • Dec 30, 2041method-of-use (U-4192)US 12295987
  • Dec 30, 2041method-of-use (U-4193)US 12295987
  • Dec 30, 2041method-of-use (U-4192)US 12295987
  • Dec 30, 2041method-of-use (U-4192)US 12295987
  • Dec 30, 2041method-of-use (U-4192)US 12295987
  • Dec 30, 2041method-of-use (U-4192)US 12295987
  • Dec 30, 2041method-of-use (U-4193)US 12295987
  • Dec 30, 2041method-of-use (U-4193)US 12295987
  • Dec 30, 2041method-of-use (U-4193)US 12295987
  • Jul 22, 2039method-of-use (U-4409)US 12343382
  • Jul 22, 2039method-of-use (U-4232)US 12343382
  • Jul 22, 2039method-of-use (U-4232)US 12343382
  • Jul 22, 2039method-of-use (U-4232)US 12343382
  • Jul 22, 2039method-of-use (U-4232)US 12343382
  • Jul 22, 2039method-of-use (U-4228)US 12343382
  • Jul 22, 2039method-of-use (U-4227)US 12343382
  • Jul 22, 2039method-of-use (U-4231)US 12343382
  • Jul 22, 2039method-of-use (U-4230)US 12343382
  • Jul 22, 2039method-of-use (U-4230)US 12343382
  • Jul 22, 2039method-of-use (U-4230)US 12343382
  • Jul 22, 2039method-of-use (U-4230)US 12343382
  • Jul 22, 2039method-of-use (U-4230)US 12343382
  • Jul 22, 2039method-of-use (U-4229)US 12343382
  • Jul 22, 2039method-of-use (U-4230)US 12343382
  • Jul 22, 2039method-of-use (U-4230)US 12343382
  • Jul 22, 2039method-of-use (U-4410)US 12343382
  • Jul 22, 2039method-of-use (U-4410)US 12343382
  • Jul 22, 2039method-of-use (U-4410)US 12343382
  • Jul 22, 2039method-of-use (U-4410)US 12343382
  • Jul 22, 2039method-of-use (U-4409)US 12343382
  • Jul 22, 2039method-of-use (U-4409)US 12343382
  • Jul 22, 2039method-of-use (U-4409)US 12343382
  • Jul 22, 2039method-of-use (U-4409)US 12343382
  • Jul 22, 2039method-of-use (U-4409)US 12343382
  • Jul 22, 2039method-of-use (U-4400)US 12343382
  • Jul 22, 2039method-of-use (U-4401)US 12343382
  • Jul 22, 2039method-of-use (U-4400)US 12343382
  • Jul 22, 2039method-of-use (U-4400)US 12343382
  • Jul 22, 2039method-of-use (U-4409)US 12343382
  • Jul 22, 2039method-of-use (U-4409)US 12343382
  • Jul 22, 2039method-of-use (U-4410)US 12343382
  • Jul 22, 2039method-of-use (U-4410)US 12343382
  • Jul 22, 2039method-of-use (U-4410)US 12343382
  • Jul 22, 2039method-of-use (U-4409)US 12343382
  • Jul 22, 2039method-of-use (U-4410)US 12343382
  • Jul 22, 2039method-of-use (U-4410)US 12343382
  • Jul 22, 2039method-of-use (U-4410)US 12343382
  • Jul 22, 2039method-of-use (U-4410)US 12343382
  • Jul 22, 2039method-of-use (U-4409)US 12343382
  • Jul 22, 2039method-of-use (U-4410)US 12343382
  • Jul 22, 2039method-of-use (U-4400)US 12343382
  • Jul 22, 2039method-of-use (U-4400)US 12343382
  • Jul 22, 2039method-of-use (U-4232)US 12343382
  • Jul 22, 2039method-of-use (U-4230)US 12343382
  • Jul 22, 2039method-of-use (U-4400)US 12343382
  • Jul 22, 2039method-of-use (U-4400)US 12343382
  • Jul 22, 2039method-of-use (U-4230)US 12343382
  • Jul 22, 2039method-of-use (U-4308)US 12453758
  • Jul 22, 2039method-of-use (U-4308)US 12453758
  • Jul 22, 2039method-of-use (U-4309)US 12453758
  • Jul 22, 2039method-of-use (U-4311)US 12453758
  • Jul 22, 2039method-of-use (U-4308)US 12453758
  • Jul 22, 2039method-of-use (U-4308)US 12453758
  • Jul 22, 2039method-of-use (U-4308)US 12453758
  • Jul 22, 2039method-of-use (U-4308)US 12453758
  • Jul 22, 2039method-of-use (U-4309)US 12453758
  • Jul 22, 2039method-of-use (U-4308)US 12453758
  • Jul 22, 2039method-of-use (U-4308)US 12453758
  • Jul 22, 2039method-of-use (U-4311)US 12453758
  • Jul 22, 2039method-of-use (U-4311)US 12453758
  • Jul 22, 2039method-of-use (U-4311)US 12453758
  • Jul 22, 2039method-of-use (U-4311)US 12453758
  • Jul 22, 2039method-of-use (U-4311)US 12453758
  • Jul 22, 2039method-of-use (U-4311)US 12453758
  • Jul 22, 2039method-of-use (U-4311)US 12453758
  • Jul 22, 2039method-of-use (U-4311)US 12453758
  • Jul 22, 2039method-of-use (U-4308)US 12453758
  • Jul 22, 2039method-of-use (U-4308)US 12453758
  • Jul 22, 2039method-of-use (U-4308)US 12453758
  • Jul 22, 2039method-of-use (U-4308)US 12453758
  • Jul 22, 2039method-of-use (U-4311)US 12453758
  • Jun 14, 2039compositionUS 11357820
  • Jun 14, 2039compositionUS 11357820
  • Jun 14, 2039formulationUS 11357820
  • Jun 14, 2039formulationUS 11357820
  • Jun 14, 2039formulationUS 11357820
  • Jun 14, 2039formulationUS 11357820
  • Jun 14, 2039formulationUS 11357820
  • Jun 14, 2039compositionUS 11357820
  • Jun 14, 2039compositionUS 11357820
  • Jun 14, 2039formulationUS 11357820
  • Jun 14, 2039formulationUS 11357820
  • Jun 14, 2039formulationUS 11357820
  • Jun 14, 2039compositionUS 11357820
  • Jun 14, 2039formulationUS 11357820
  • Jun 14, 2039formulationUS 11357820
  • Jun 14, 2039formulationUS 11357820
  • Jun 14, 2039formulationUS 11357820
  • Jun 14, 2039formulationUS 11357820
  • Jun 14, 2039formulationUS 11357820
  • Jun 14, 2039formulationUS 11357820
  • Jun 14, 2039formulationUS 11357820
  • Jun 14, 2039formulationUS 11357820
  • Jun 14, 2039compositionUS 11357820
  • Jun 14, 2039formulationUS 11357820
  • Jun 14, 2039method-of-use (U-3855)US 11918623
  • Jun 14, 2039method-of-use (U-3855)US 11918623
  • Jun 14, 2039method-of-use (U-3855)US 11918623
  • Jun 14, 2039method-of-use (U-3855)US 11918623
  • Jun 14, 2039method-of-use (U-3855)US 11918623
  • Jun 14, 2039method-of-use (U-3855)US 11918623
  • Jun 14, 2039method-of-use (U-3855)US 11918623
  • Jun 14, 2039method-of-use (U-3855)US 11918623
  • Jun 14, 2039method-of-use (U-3855)US 11918623
  • Jun 14, 2039method-of-use (U-3855)US 11918623
  • Jun 14, 2039method-of-use (U-3855)US 11918623
  • Jun 14, 2039method-of-use (U-3855)US 11918623
  • Jun 14, 2039method-of-use (U-4377)US 12453755
  • Jun 14, 2039method-of-use (U-4385)US 12453755
  • Jun 14, 2039method-of-use (U-4386)US 12453755
  • Jun 14, 2039method-of-use (U-4378)US 12453755
  • Jun 14, 2039method-of-use (U-4386)US 12453755
  • Jun 14, 2039method-of-use (U-4381)US 12453755
  • Jun 14, 2039method-of-use (U-4380)US 12453755
  • Jun 14, 2039method-of-use (U-4377)US 12453755
  • Jun 14, 2039method-of-use (U-4378)US 12453755
  • Jun 14, 2039method-of-use (U-4386)US 12453755
  • Jun 14, 2039method-of-use (U-4376)US 12453755
  • Jun 14, 2039method-of-use (U-4383)US 12453755
  • Jun 14, 2039formulationUS 12453756
  • Jun 14, 2039formulationUS 12453756
  • Jun 14, 2039formulationUS 12453756
  • Jun 14, 2039formulationUS 12453756
  • Jun 14, 2039formulationUS 12453756
  • Jun 14, 2039formulationUS 12453756
  • Jun 14, 2039formulationUS 12453756
  • Jun 14, 2039formulationUS 12453756
  • Jun 14, 2039formulationUS 12453756
  • Jun 14, 2039formulationUS 12453756
  • Jun 14, 2039formulationUS 12453756
  • Jun 14, 2039formulationUS 12453756
  • Jun 14, 2039formulationUS 12453756
  • Jun 14, 2039formulationUS 12453756
  • Jun 14, 2039formulationUS 12453756
  • Jun 14, 2039formulationUS 12453756
  • Jun 14, 2039formulationUS 12453756
  • Jun 14, 2039formulationUS 12453756
  • Jun 14, 2039formulationUS 12453756
  • Jun 14, 2039formulationUS 12453756
  • Jun 14, 2039formulationUS 12453756
  • Jun 14, 2039formulationUS 12453756
  • Jun 14, 2039formulationUS 12453756
  • Jun 14, 2039formulationUS 12453756
  • Jan 5, 2036compositionUS 9474780
  • Jan 5, 2036compositionUS 9474780
  • Jan 5, 2036compositionUS 9474780
  • Jan 5, 2036compositionUS 9474780
  • Jan 5, 2036compositionUS 9474780
  • Jan 5, 2036compositionUS 9474780
  • Jan 5, 2036compositionUS 9474780
  • Jan 5, 2036compositionUS 9474780
  • Jan 5, 2036compositionUS 9474780
  • Jan 5, 2036compositionUS 9474780
  • Jan 5, 2036compositionUS 9474780
  • Jan 5, 2036compositionUS 9474780
  • Jan 5, 2036compositionUS 9474780
  • Jan 5, 2036compositionUS 9474780
  • Jan 5, 2036compositionUS 9474780
  • Jan 5, 2036compositionUS 9474780
  • Jan 5, 2036compositionUS 9474780
  • Jan 5, 2036compositionUS 9474780
  • Jan 5, 2036compositionUS 9474780
  • Jan 5, 2036compositionUS 9474780
  • Jan 5, 2036compositionUS 9474780
  • Jan 5, 2036compositionUS 9474780
  • Jan 5, 2036compositionUS 9474780
  • Jan 5, 2036compositionUS 9474780
  • Jan 5, 2036compositionUS 9474780
  • Jan 5, 2036compositionUS 9474780
  • Jan 5, 2036compositionUS 9474780
  • Jan 5, 2036compositionUS 9474780
  • Jan 5, 2036compositionUS 9474780
  • Jan 5, 2036compositionUS 9474780
  • Jan 5, 2036compositionUS 9474780
  • Jan 5, 2036compositionUS 9474780
  • Jan 5, 2036compositionUS 9474780
  • Jan 5, 2036compositionUS 9474780
  • Jan 5, 2036compositionUS 9474780
  • Jan 5, 2036compositionUS 9474780
  • Jan 5, 2036compositionUS 9474780
  • Jan 5, 2036compositionUS 9474780
  • Jan 5, 2036compositionUS 9474780
  • Jan 5, 2036compositionUS 9474780
  • Jan 5, 2036compositionUS 9474780
  • Jan 5, 2036compositionUS 9474780
  • Jan 5, 2036compositionUS 9474780
  • Jan 5, 2036compositionUS 9474780
  • Jan 5, 2036compositionUS 9474780
  • Jan 5, 2036compositionUS 9474780
  • Jan 5, 2036compositionUS 9474780
  • Jan 5, 2036compositionUS 9474780

FDA exclusivities (62)

  • Dec 19, 2028NPPNew Product (3y)2.1y
  • Dec 19, 2028NPPNew Product (3y)2.1y
  • Dec 19, 2028NPPNew Product (3y)2.1y
  • Dec 19, 2028NPPNew Product (3y)2.1y
  • Dec 19, 2028NPPNew Product (3y)2.1y
  • Dec 19, 2028NPPNew Product (3y)2.1y
  • Dec 19, 2028NPPNew Product (3y)2.1y
  • Dec 19, 2028NPPNew Product (3y)2.1y
  • Dec 20, 2027I-958Indication (3y)1.1y
  • Dec 20, 2027I-958Indication (3y)1.1y
  • Dec 20, 2027I-958Indication (3y)1.1y
  • Dec 20, 2027I-958Indication (3y)1.1y
  • Dec 20, 2027I-958Indication (3y)1.1y
  • Dec 20, 2027I-958Indication (3y)1.1y
  • Dec 20, 2027I-958Indication (3y)1.1y
  • Dec 20, 2027I-958Indication (3y)1.1y
  • Dec 20, 2027I-958Indication (3y)1.1y
  • Dec 20, 2027I-958Indication (3y)1.1y
  • Dec 20, 2027I-958Indication (3y)1.1y
  • Dec 20, 2027I-958Indication (3y)1.1y
  • Oct 18, 2027M-82Method (3y)332d
  • Oct 18, 2027M-82Method (3y)332d
  • Oct 18, 2027M-82Method (3y)332d
  • Oct 18, 2027M-82Method (3y)332d
  • Oct 18, 2027M-82Method (3y)332d
  • Oct 18, 2027M-82Method (3y)332d
  • Oct 18, 2027M-82Method (3y)332d
  • Oct 18, 2027M-82Method (3y)332d
  • Oct 18, 2027M-82Method (3y)332d
  • Oct 18, 2027M-82Method (3y)332d
  • Oct 18, 2027M-82Method (3y)332d
  • Oct 18, 2027M-82Method (3y)332d
  • May 13, 2027NCENew Chemical Entity (5y)174d
  • May 13, 2027NCENew Chemical Entity (5y)174d
  • May 13, 2027NCENew Chemical Entity (5y)174d
  • May 13, 2027NCENew Chemical Entity (5y)174d
  • May 13, 2027NCENew Chemical Entity (5y)174d
  • May 13, 2027NCENew Chemical Entity (5y)174d
  • May 13, 2027NCENew Chemical Entity (5y)174d
  • May 13, 2027NCENew Chemical Entity (5y)174d
  • May 13, 2027NCENew Chemical Entity (5y)174d
  • May 13, 2027NCENew Chemical Entity (5y)174d
  • May 13, 2027NCENew Chemical Entity (5y)174d
  • May 13, 2027NCENew Chemical Entity (5y)174d
  • May 13, 2027NCENew Chemical Entity (5y)174d
  • May 13, 2027NCENew Chemical Entity (5y)174d
  • May 13, 2027NCENew Chemical Entity (5y)174d
  • May 13, 2027NCENew Chemical Entity (5y)174d
  • May 13, 2027NCENew Chemical Entity (5y)174d
  • May 13, 2027NCENew Chemical Entity (5y)174d
  • May 13, 2027NCENew Chemical Entity (5y)174d
  • May 13, 2027NCENew Chemical Entity (5y)174d
  • May 13, 2027NCENew Chemical Entity (5y)174d
  • May 13, 2027NCENew Chemical Entity (5y)174d
  • May 13, 2027NCENew Chemical Entity (5y)174d
  • May 13, 2027NCENew Chemical Entity (5y)174d
  • Nov 8, 2026NPNP
  • Nov 8, 2026NPNP
  • Nov 8, 2026NPNP
  • Nov 8, 2026NPNP
  • Nov 8, 2026NPNP
  • Nov 8, 2026NPNP

News(10)

  • ‘Selling and marketing snake oil’: The debate over compounded GLP-1s
    Proponents of compounding argue it increases access, lowers prices and helps patients who may need individualized versions of a drug. But there are serious concerns, experts said at the HLTH confer…
    biopharma_dive · 18h ago
  • Novo’s CagriSema drives more than 20% weight loss at lower doses
    As Novo awaits an FDA decision for its next-gen obesity asset, the company has presented more data at ObesityWeek that could help buoy sentiment on the amylin/GLP-1 combination that disappointed in…
    biospace · 2d ago
  • STAT+: Pharmalittle: We’re reading about GLP-1 use, Covid-19 vaccine investment returns, and more
    During July and August 2025, approximately 1 in 10 U.S. adults reported taking a GLP-1 medication during the previous year
    stat · 2d ago
  • STAT+: Up and down the ladder: The latest comings and goings
    From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.
    stat · 5d ago
  • STAT+: Pharmalittle: We’re reading about Lilly conflict questions, a DEA OK for a narcolepsy pill, and more
    A deal for smart-ring maker Oura to acquire a telehealth company is raising conflict-of-interest questions for Eli Lilly
    stat · 5d ago
  • Biopharma pushes beyond GLP-1s, weight loss at ObesityWeek 2026
    ObesityWeek 2026, which kicks off on Saturday, will spotlight presentations on the ascendant amylin pathway, as well as therapies looking to improve the quality of weight loss and patients’ persist…
    biospace · 6d ago
  • Deep dive: Cardiovascular calamities and catalysts
    BioSpace reviews upcoming cardiovascular milestones after a summer of missed targets.
    biospace · 6d ago
  • Blackstone bets $1.5B on Pfizer’s obesity drug
    The deal will support a sprawling Phase 3 program for a monthly GLP-1 shot Pfizer acquired by winning a bidding war for the drug’s previous owner, Metsera.
    biopharma_dive · 6d ago
  • STAT+: Pharmalittle: We’re reading about FDA shelving fast-track review, a Canadian importer arrested, and more
    The FDA has shelved the fast-track drug review initiative launched in June 2025 by former Commissioner Marty Makary
    stat · 6d ago
  • STAT+: Most-favored nations policy makes drugmakers rethink launches abroad
    Drug companies seem to be looking for workarounds to protect their U.S. sales against Trump's "most-favored nations" policy:
    stat · 7d ago
view all news mentions →
brand
ZEPBOUND
trade names
Mounjaro, Mounjaro (autoinjector), Zepbound, Zepbound (autoinjector)
generic
TIRZEPATIDE
MOA
12.1 Mechanism of Action Tirzepatide is a GIP receptor and GLP-1 receptor agonist. It contains a C20 fatty diacid that enables albumin binding and prolongs the half-life. Tirzepatide selectively binds to and activates both the GIP and GLP-1 receptors, the targets for native GIP and GLP-1. GLP-1 is a physiological regulator of appetite and caloric intake. Nonclinical studies suggest the addition of GIP may further contribute to the regulation of food intake. Both GIP receptors and GLP-1 receptors are found in areas of the brain involved in appetite regulation. Animal studies show that tirzepatide distributes to and activates neurons in brain regions involved in regulation of appetite and food intake.
indication
type 2 diabetes
phase
marketed
approved
2022-05-13
Data sources
openFDA · ClinicalTrials.gov · OpenTargets
last refreshed 2h ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?